Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Business
STAT+

Puma Biotech finds European regulators inhospitable to breast cancer drug approval

  • Adam Feuerstein

By Adam Feuerstein Jan. 23, 2018

Reprints

Puma Biotechnology (PBYI) has a European problem.

Scientific advisers attached to the European Medicines Agency (EMA) issued a “negative trend vote” Tuesday on Puma’s breast cancer drug Nerlynx — an indication they’d be unwilling to issue a recommendation favoring approval.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Focus Covid booster campaigns on high-risk people, WHO’s vaccine…
Focus Covid booster campaigns on high-risk people, WHO’s vaccine experts recommend
To gin up opposition to the proposed menthol ban,…
To gin up opposition to the proposed menthol ban, tobacco companies are turning to gas station…
Drug used to halt puberty in children may cause…
Drug used to halt puberty in children may cause lasting health problems
Pharmalittle: WHO may add obesity drugs to essential medicines…
Pharmalittle: WHO may add obesity drugs to essential medicines list; monkey shortage may delay drug development
Medical device companies now need to prove to FDA…
Medical device companies now need to prove to FDA they’re protected against cyberattacks
Shortage of monkeys for early-stage research jeopardizes timelines for…
Shortage of monkeys for early-stage research jeopardizes timelines for developing some drugs

Recommended Stories